FTC v. Express Scripts

Express Scripts, Inc. allegedly artificially inflated the list price of insulin drugs by using anticompetitive and unfair rebating practices, and impaired patients’ access to lower list price products, ultimately shifting the cost of high insulin list prices to vulnerable patients. According to the FTC's complaint, the inflated list prices hurt patients whose out-of-pocket payments like copays and coinsurance are tied to the list price of the drug.

Summary generated from official Federal Trade Commission press release